Advanced search
1 file | 595.79 KB Add to list

Clinical presentation of sporadic and hereditary pheochromocytoma/paraganglioma

Author
Organization
Abstract
Pheochromocytomas (PHEO) and paragangliomas (PGL) can occur sporadic or within genetic predisposition syndromes. Despite shared embryology, there are important differences between PHEO and PGL. The aim of this study was to describe the clinical presentation and disease characteristics of PHEO/PGL. A retrospective analysis of consecutively registered patients diagnosed with or treated for PHEO/PGL in a tertiary care centre was performed. Patients were compared according to anatomic location (PHEO vs PGL) and genetic status (sporadic vs hereditary). In total, we identified 38 women and 29 men, aged 50 ± 19 years. Of these, 42 (63%) had PHEO, and 25 (37%) had PGL. Patients with PHEO presented more frequently with sporadic than hereditary disease (45 years vs 27 (77%) vs 8 (23%)) than patients with PGL (9 (36%) vs 16 (64%), respectively) and were older at diagnosis (55 ± 17 vs 40 ± 18 years, <jats:italic>P</jats:italic> = 0.001), respectively). About half of the cases in both PHEO and PGL were diagnosed due to disease-related symptoms. In patients with PHEO, tumour diameter was larger (<jats:italic>P</jats:italic> = 0.001), metanephrine levels higher (<jats:italic>P</jats:italic> = 0.02), and there was more frequently a history of cardiovascular events than in patients with PGL. In conclusion, we found that patients with PGL more frequently have a hereditary predisposition than those with PHEO, contributing to the fact that diagnosis is generally made earlier in PGL. Although diagnosis in both PHEO and PGL was mostly due to related symptoms, patients with PHEO more often presented with cardiovascular comorbidities than those with PGL which might relate to a higher number of functionally active tumours in the former.
Keywords
General Medicine

Downloads

  • 2634-4793-EO-22-0040.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 595.79 KB

Citation

Please use this url to cite or link to this publication:

MLA
Lider Burciulescu, Sofia Maria, et al. “Clinical Presentation of Sporadic and Hereditary Pheochromocytoma/Paraganglioma.” ENDOCRINE ONCOLOGY, vol. 3, no. 1, Bioscientifica, 2023, doi:10.1530/eo-22-0040.
APA
Lider Burciulescu, S. M., Randon, C., Duprez, F., Huvenne, W., Creytens, D., Claes, K., … Lapauw, B. (2023). Clinical presentation of sporadic and hereditary pheochromocytoma/paraganglioma. ENDOCRINE ONCOLOGY, 3(1). https://doi.org/10.1530/eo-22-0040
Chicago author-date
Lider Burciulescu, Sofia Maria, Caren Randon, Fréderic Duprez, Wouter Huvenne, David Creytens, Kathleen Claes, Robin de Putter, Guy T’Sjoen, Corin Badiu, and Bruno Lapauw. 2023. “Clinical Presentation of Sporadic and Hereditary Pheochromocytoma/Paraganglioma.” ENDOCRINE ONCOLOGY 3 (1). https://doi.org/10.1530/eo-22-0040.
Chicago author-date (all authors)
Lider Burciulescu, Sofia Maria, Caren Randon, Fréderic Duprez, Wouter Huvenne, David Creytens, Kathleen Claes, Robin de Putter, Guy T’Sjoen, Corin Badiu, and Bruno Lapauw. 2023. “Clinical Presentation of Sporadic and Hereditary Pheochromocytoma/Paraganglioma.” ENDOCRINE ONCOLOGY 3 (1). doi:10.1530/eo-22-0040.
Vancouver
1.
Lider Burciulescu SM, Randon C, Duprez F, Huvenne W, Creytens D, Claes K, et al. Clinical presentation of sporadic and hereditary pheochromocytoma/paraganglioma. ENDOCRINE ONCOLOGY. 2023;3(1).
IEEE
[1]
S. M. Lider Burciulescu et al., “Clinical presentation of sporadic and hereditary pheochromocytoma/paraganglioma,” ENDOCRINE ONCOLOGY, vol. 3, no. 1, 2023.
@article{01GTE6VBF5J8AZ4MM99B2CRY65,
  abstract     = {{Pheochromocytomas (PHEO) and paragangliomas (PGL) can occur sporadic or within genetic predisposition syndromes. Despite shared embryology, there are important differences between PHEO and PGL. The aim of this study was to describe the clinical presentation and disease characteristics of PHEO/PGL. A retrospective analysis of consecutively registered patients diagnosed with or treated for PHEO/PGL in a tertiary care centre was performed. Patients were compared according to anatomic location (PHEO vs PGL) and genetic status (sporadic vs hereditary). In total, we identified 38 women and 29 men, aged 50 ± 19 years. Of these, 42 (63%) had PHEO, and 25 (37%) had PGL. Patients with PHEO presented more frequently with sporadic than hereditary disease (45 years vs 27 (77%) vs 8 (23%)) than patients with PGL (9 (36%) vs 16 (64%), respectively) and were older at diagnosis (55 ± 17 vs 40 ± 18 years, <jats:italic>P</jats:italic> = 0.001), respectively). About half of the cases in both PHEO and PGL were diagnosed due to disease-related symptoms. In patients with PHEO, tumour diameter was larger (<jats:italic>P</jats:italic> = 0.001), metanephrine levels higher (<jats:italic>P</jats:italic> = 0.02), and there was more frequently a history of cardiovascular events than in patients with PGL. In conclusion, we found that patients with PGL more frequently have a hereditary predisposition than those with PHEO, contributing to the fact that diagnosis is generally made earlier in PGL. Although diagnosis in both PHEO and PGL was mostly due to related symptoms, patients with PHEO more often presented with cardiovascular comorbidities than those with PGL which might relate to a higher number of functionally active tumours in the former.}},
  articleno    = {{e220040}},
  author       = {{Lider Burciulescu, Sofia Maria and Randon, Caren and Duprez, Fréderic and Huvenne, Wouter and Creytens, David and Claes, Kathleen and de Putter, Robin and T'Sjoen, Guy and Badiu, Corin and Lapauw, Bruno}},
  issn         = {{2634-4793}},
  journal      = {{ENDOCRINE ONCOLOGY}},
  keywords     = {{General Medicine}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{9}},
  publisher    = {{Bioscientifica}},
  title        = {{Clinical presentation of sporadic and hereditary pheochromocytoma/paraganglioma}},
  url          = {{http://doi.org/10.1530/eo-22-0040}},
  volume       = {{3}},
  year         = {{2023}},
}

Altmetric
View in Altmetric